Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 386/kg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| B | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| C | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AMG 386 placebo | DRUG | AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death |
| AMG 386 10mg/kg | DRUG | AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death |
| AMG 386 3mg/kg | DRUG | AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death |
| Cisplatin | DRUG | Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death |
| Capecitabine | DRUG | Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death |
Inclusion Criteria: * Disease Related * Histologically or cytologically confirmed adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus with metastatic disease * Measurable or non-measurable disease per RECIST Guidelines * Prior gastrectomy (total or partial) may be al...
AMG 386 is an investigational oncology drug being studied for advanced renal cell carcinoma, advanced solid tumors, carcinoma, gastrointestinal cancer, fallopian tube cancer, and locally recurrent and metastatic breast cancer. It is in Phase 2 clinical development and is not yet approved by the FDA.
AMG 386 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is an investigational small molecule in Phase 2 clinical development for multiple oncology indications.
AMG 386 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials have been completed, including a Phase 2 study in advanced renal cell carcinoma.
AMG 386 has been studied in several completed clinical trials, including NCT00467025, a Phase 2 study in advanced renal cell carcinoma; NCT01331941, a pharmacokinetic study in advanced solid tumors and renal impairment; NCT01666977, a Phase 1b/2 trial in non-small cell lung cancer; and NCT01992341, a drug-drug interaction study with paclitaxel.
AMG 386 is also known as trebananib. It is an investigational oncology drug being developed by Amgen Inc. for multiple cancer types, including advanced renal cell carcinoma and advanced solid tumors.